Disc Medicine to Participate in SVB Securities Global Biopharma Conference
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company, announced that CEO John Quisel will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 16, 2023, at 8:40 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company, announced that CEO John Quisel will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 16, 2023, at 8:40 a.m. ET. The event will be held virtually, and a live webcast can be accessed via the investor relations section of the company's website. Disc Medicine focuses on developing novel treatments for serious hematologic diseases, targeting key biological pathways, including heme biosynthesis and iron homeostasis. For further details, visit the company's website.
Details
News Market Reaction – IRON
The recorded move for IRON in the trading session of this news was -3.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat in a virtual format at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 8:40 a.m. ET.
A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available.
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Verge Scientific Communications
prusconi@vergescientific.com
Investor Relations Contact
Suzanne Messere
Stern Investor Relations
suzanne.messere@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.